A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma

Trial Profile

A Randomized, Double-blind Phase 2 Study Comparing Gemcitabine and Cisplatin in Combination With OGX-427 or Placebo in Patients With Advanced Transitional Cell Carcinoma

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2017

At a glance

  • Drugs Apatorsen (Primary) ; Cisplatin; Gemcitabine
  • Indications Bladder cancer; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms Borealis-1
  • Sponsors Achieve Life Sciences; OncoGenex Pharmaceuticals; OncoGenex Technologies
  • Most Recent Events

    • 01 Oct 2017 Primary endpoint (Overall survival) has not been met as per the results published in the Annals of Oncology
    • 01 Oct 2017 Results published in the Annals of Oncology
    • 12 Nov 2015 According to an OncoGenex media release, results from this trial will be presented at the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC 2015).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top